JP2024505195A5 - - Google Patents
Info
- Publication number
- JP2024505195A5 JP2024505195A5 JP2023544526A JP2023544526A JP2024505195A5 JP 2024505195 A5 JP2024505195 A5 JP 2024505195A5 JP 2023544526 A JP2023544526 A JP 2023544526A JP 2023544526 A JP2023544526 A JP 2023544526A JP 2024505195 A5 JP2024505195 A5 JP 2024505195A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141030P | 2021-01-25 | 2021-01-25 | |
| US63/141,030 | 2021-01-25 | ||
| PCT/US2022/013666 WO2022159875A1 (en) | 2021-01-25 | 2022-01-25 | Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024505195A JP2024505195A (ja) | 2024-02-05 |
| JPWO2022159875A5 JPWO2022159875A5 (https=) | 2025-01-30 |
| JP2024505195A5 true JP2024505195A5 (https=) | 2025-01-30 |
Family
ID=80446637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544526A Pending JP2024505195A (ja) | 2021-01-25 | 2022-01-25 | 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12030935B2 (https=) |
| EP (1) | EP4281475A1 (https=) |
| JP (1) | JP2024505195A (https=) |
| KR (1) | KR20230135627A (https=) |
| CN (1) | CN116964088A (https=) |
| AU (1) | AU2022210475A1 (https=) |
| BR (1) | BR112023014337A8 (https=) |
| CA (1) | CA3205846A1 (https=) |
| CL (1) | CL2023002148A1 (https=) |
| CO (1) | CO2023010900A2 (https=) |
| IL (1) | IL304505A (https=) |
| MX (1) | MX2023008691A (https=) |
| WO (1) | WO2022159875A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120028552B (zh) * | 2025-02-28 | 2025-08-19 | 上海交通大学医学院附属上海儿童医学中心 | 血小板衍生生长因子pdgf-d在评估右心衰竭中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| HK1216428A1 (zh) * | 2012-11-09 | 2016-11-11 | 辉瑞公司 | 血小板衍生生长因子b之特异性抗体及其组合物和用途 |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| CN107148429B (zh) | 2014-11-10 | 2021-12-03 | 豪夫迈·罗氏有限公司 | 抗-pdgf-b抗体和使用方法 |
-
2022
- 2022-01-25 MX MX2023008691A patent/MX2023008691A/es unknown
- 2022-01-25 KR KR1020237028422A patent/KR20230135627A/ko active Pending
- 2022-01-25 EP EP22704144.9A patent/EP4281475A1/en active Pending
- 2022-01-25 CA CA3205846A patent/CA3205846A1/en active Pending
- 2022-01-25 US US17/583,930 patent/US12030935B2/en active Active
- 2022-01-25 WO PCT/US2022/013666 patent/WO2022159875A1/en not_active Ceased
- 2022-01-25 AU AU2022210475A patent/AU2022210475A1/en active Pending
- 2022-01-25 BR BR112023014337A patent/BR112023014337A8/pt unknown
- 2022-01-25 CN CN202280017601.6A patent/CN116964088A/zh active Pending
- 2022-01-25 JP JP2023544526A patent/JP2024505195A/ja active Pending
-
2023
- 2023-07-17 IL IL304505A patent/IL304505A/en unknown
- 2023-07-21 CL CL2023002148A patent/CL2023002148A1/es unknown
- 2023-08-22 CO CONC2023/0010900A patent/CO2023010900A2/es unknown
-
2024
- 2024-05-24 US US18/673,771 patent/US20240425574A1/en active Pending